$REGN News

Regeneron Secures FDA Approval for Rare Genetic Disorder Drug

Regeneron to challenge Ipsen as FDA clears bone disease drug

Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug

Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy

Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News

Regeneron Announces Investor Conference Presentations

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)

Regeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva

Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?

If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?

Regeneron Pharmaceuticals (REGN) Keeps Buybacks And Dividend In Focus As Fair Value Stays In Sight

NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues

LibtayoReceives Health Canada Approval for Adjuvant Treatment Of High-Risk Cutaneous Squamous Cell Carcinoma

Regeneron Founder and CEO Leonard Schleifer on America’s entrepreneurial spirit

Surging Earnings Estimates Signal Upside for Regeneron (REGN) Stock

REGN or INCY: Which Is the Better Value Stock Right Now?

Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030